| Swiss community-based surveillance of respiratory virus co-occurrence in 2022–2024 | Microbiology spectrum |  | | 2026 | 8 | 5 |
|
| Swiss public health measures associated with reduced SARS-CoV-2 transmission using genome data | Science translational medicine | | | 2023 | 86 | 86 |
|
| Prevalence of immunoglobulin G (IgG) against severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) andeEvaluation of a rapid MEDsan IgG test in children seeking medical care | Clinical Infectious Diseases | | | 2021 | 307 | 428 |
|
| SARS-CoV-2 N501Y introductions and transmissions in Switzerland from beginning of october 2020 to february 2021-implementation of swiss-wide diagnostic screening and whole genome sequencing | Microorganisms | | | 2021 | 247 | 401 |
|
| Antigen Extraction and B Cell Activation Enable Identification of Rare Membrane Antigen Specific Human B Cells | Frontiers in Immunology | | | 2019 | 366 | 235 |
|
| Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient | Antiviral Therapy | | | 2019 | 284 | 316 |
|
| Comparative analysis of viral shedding in pediatric and adult subjects with central nervous system-associated enterovirus infections from 2013 to 2015 in Switzerland | Journal of Clinical Virology | | | 2017 | 595 | 271 |
|
| Hospital surveillance of influenza strains: a concordant image of viruses identified by the Swiss Sentinel system? | Influenza and other Respiratory Viruses | | | 2017 | 1,478 | 563 |
|
| Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe : Preliminary Report | The New England journal of medicine | | | 2016 | 938 | 302 |
|
| The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial | Lancet. Infectious diseases |  | | 2015 | 710 | 0 |
|
